Gene Therapy & CRISPR — Explain gene therapy/CRISPR concepts at a high level (intro)

For much of the twentieth century, physicians treating genetic disorders could only manage symptoms—administering insulin for diabetes, transfusing blood for sickle-cell anemia, or prescribing enzyme supplements for metabolic deficiencies. The underlying mutations persisted in patients' genomes, passed faithfully from cell to daughter cell. The conceptual breakthrough of gene therapy was the realization that if disease originates in DNA, the most elegant cure would be to correct or replace the defective sequence itself. This ambition set the stage for decades of molecular-biology research that would ultimately converge on a bacterial immune system repurposed as the most precise genome-editing tool ever devised: CRISPR-Cas9.

The trajectory from Friedmann's theoretical paper to FDA-approved CRISPR treatments spans roughly fifty years and encompasses triumphs, setbacks—including the tragic death of Jesse Gelsinger in a 1999 adenovirus trial—and paradigm shifts in delivery technology. The central question this lesson addresses is deceptively simple: How can we introduce, correct, or silence specific genes within living human cells to treat or cure disease?

Gene therapy and genome editing rest on several foundational ideas drawn from molecular genetics, virology, and enzymology. Understanding these principles provides the conceptual scaffold upon which every clinical application is built. At the most general level, gene therapy seeks to alter the genetic instruction set inside a patient's cells; the distinction among strategies lies in how that alteration is achieved and whether the change is permanent or transient.

The beauty of the CRISPR system lies in its modularity. To retarget Cas9 to a different genomic locus, one simply synthesizes a new 20-nucleotide guide sequence—no protein engineering required. This stands in stark contrast to earlier genome-editing platforms such as zinc-finger nucleases (ZFNs) and TALENs, which require laborious protein redesign for each new target. The simplicity of guide-RNA design has democratized genome editing, enabling even modestly funded laboratories to perform gene knockouts, knock-ins, and regulatory perturbations with high efficiency.

Viral Vector Delivery

The most widely used viral vector for in vivo gene therapy is the adeno-associated virus (AAV). AAV is a small, non-enveloped parvovirus with a ~4.7 kb single-stranded DNA genome. For therapeutic use, the viral coding sequences (rep and cap) are removed and replaced with the transgene expression cassette flanked by inverted terminal repeats (ITRs). Because AAV genomes persist predominantly as extrachromosomal episomes in non-dividing cells, the risk of insertional mutagenesis is low relative to integrating vectors such as lentiviruses. However, AAV's limited packaging capacity (~4.7 kb) constrains the size of the therapeutic transgene, which has spurred development of dual-vector strategies and smaller Cas orthologs (e.g., SaCas9 at ~3.2 kb).

Non-Viral Delivery: Lipid Nanoparticles

An increasingly prominent non-viral strategy uses lipid nanoparticles (LNPs) to encapsulate mRNA encoding Cas9 along with the sgRNA. LNPs exploit endocytosis and endosomal escape to deliver their cargo to the cytoplasm, where the mRNA is translated by host ribosomes. Because the Cas9 mRNA is transient—degraded within hours to days—LNP delivery produces a pulse of editing activity followed by clearance, which may reduce off-target accumulation compared to constitutive expression from a viral vector. This approach was validated by Intellia Therapeutics in their NTLA-2001 program for transthyretin amyloidosis, representing a milestone in in vivo LNP-delivered CRISPR therapy.

DNA Repair Pathway Kinetics

After Cas9 generates a DSB, the ratio of NHEJ to HDR outcomes is a critical determinant of therapeutic success. In most mammalian somatic cells, NHEJ dominates because it is active throughout the cell cycle, whereas HDR is largely restricted to the S and G2 phases when a sister chromatid is available as a repair template. For applications requiring precise correction (e.g., inserting a normal allele), researchers have explored cell-cycle synchronization, small-molecule inhibition of NHEJ factors like DNA-PKcs, or alternative editing strategies such as base editing and prime editing, which avoid DSBs altogether.

Sickle-cell disease (SCD) results from a single nucleotide substitution (A→T) in the HBB gene, converting codon 6 from GAG (glutamic acid) to GTG (valine). The mutant hemoglobin S (HbS) polymerizes under low-oxygen conditions, distorting red blood cells into a sickle shape. Let us walk through the reasoning a gene-therapy scientist would use to design a CRISPR-based therapeutic strategy.

While CRISPR-Cas9 remains the workhorse of genome editing, its reliance on double-strand breaks introduces risks of large deletions, chromosomal translocations, and p53-mediated cell-cycle arrest. These limitations have driven the development of next-generation editing tools that either avoid DSBs entirely or expand the repertoire of possible modifications. Understanding where standard CRISPR fits within this evolving landscape is essential for appreciating both its current clinical value and its future trajectory.

The field is moving rapidly toward DSB-free editing as the default paradigm, with base editors and prime editors likely to supplant standard Cas9 for many therapeutic indications. Additionally, emerging tools such as epigenome editors (CRISPRi/CRISPRa) offer reversible gene silencing or activation without altering the DNA sequence at all—adding yet another layer of therapeutic versatility. Students entering the field today should expect the molecular toolkit to continue expanding at an accelerating pace.